Proton-pump inhibitor-induced bone loss is preventable by concomitant use of a long-acting somatostatin analogue
Authors:
Open Access
- 1 February 2024
- journal article
- research article
- Vol. 27 (2) , 165-169
Abstract
Objective(s): Long-term consumption of pump inhibitors causes osteoporosis. Some possible mechanisms are gastrin over-secretion and hypochlorhydria. Octreotide is a somatostatin analog that inhibits the secretion of many hormones such as gastrin. This study aimed to assess the effects of pantoprazole on the bone when used with octreotide in an animal model.Materials and Methods: Forty-eight male Wistar rats were randomly assigned into 4 groups: A) pantoprazole 3 mg/Kg/day orally; B) Sandostatin LAR 1 mg/month intramuscular injection; C) Pantoprazole and Sandostatin LAR; and D) Control group. After 90 days of the experiment, bone densitometry was done and serum and urine samples were collected for analysis.Results: The results indicated a significant decrease in the global, spine, femur, and tibia bone mineral density (BMD) and bone mineral content (BMC) in the pantoprazole group compared to the control group (P<0.05). There was a significant increase in the levels of PTH, gastrin, and alkaline phosphatase (ALP) in the pantoprazole group compared to the control group (P<0.05). There was no significant difference in the serum levels of gastrin, PTH, ALP, and also BMD in the rats that received sandostatin+ pantoprazole or sandostatin alone, compared to the control group.Conclusion: This study showed that the pantoprazole-induced bone loss, through elevation of serum gastrin and PTH, was preventable by concomitant use of a long-acting somatostatin analog.Keywords
This publication has 37 references indexed in Scilit:
- Applying the ARRIVE Guidelines to an In Vivo DatabasePLOS Biology, 2015
- An estimate of the worldwide prevalence and disability associated with osteoporotic fracturesOsteoporosis International, 2006
- Octreotide Abolishes the Acute Decrease in Bone Turnover in Response to Oral GlucoseThe Journal of Clinical Endocrinology & Metabolism, 2003
- The Somatostatin Analog Octreotide Inhibits GH-Stimulated, But Not IGF-I-Stimulated, Bone Growth in Hypophysectomized RatsEndocrinology, 2002
- Chicken Parathyroid Hormone Gene Expression in Response to Gastrin, Omeprazole, Ergocalciferol, and Restricted Food IntakeCalcified Tissue International, 1997
- OctreotideNew England Journal of Medicine, 1996
- Management of Gastroenteropancreatic Endocrine Tumors: The Place of Somatostatin AnaloguesDigestion, 1994
- Lack of Effect of Octreotide on Parathyroid Hormone Levels and Urinary Excretion of Epidermal Growth FactorHormone and Metabolic Research, 1993
- The Parathyroid Glands in Experimentally Induced Hypergastrinemia in the RatScandinavian Journal of Gastroenterology, 1977
- Hypothalamic Polypeptide That Inhibits the Secretion of Immunoreactive Pituitary Growth HormoneScience, 1973